Trial Profile
A Randomized, Open-label, 2×2 Crossover, Phase I Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-536 Pediatric Formulations and TAK-536 Commercial Tablet in Healthy Adult Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors Takeda
- 01 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 27 Apr 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 31 Mar 2015 New trial record